IL122385A - Composition for sustained release of human growth hormone - Google Patents

Composition for sustained release of human growth hormone

Info

Publication number
IL122385A
IL122385A IL12238596A IL12238596A IL122385A IL 122385 A IL122385 A IL 122385A IL 12238596 A IL12238596 A IL 12238596A IL 12238596 A IL12238596 A IL 12238596A IL 122385 A IL122385 A IL 122385A
Authority
IL
Israel
Prior art keywords
composition
sustained release
hgh
biologically active
polymer
Prior art date
Application number
IL12238596A
Other languages
English (en)
Other versions
IL122385A0 (en
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/477,725 external-priority patent/US5667808A/en
Application filed by Alkermes Inc filed Critical Alkermes Inc
Publication of IL122385A0 publication Critical patent/IL122385A0/xx
Publication of IL122385A publication Critical patent/IL122385A/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL12238596A 1995-06-07 1996-06-03 Composition for sustained release of human growth hormone IL122385A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/477,725 US5667808A (en) 1992-12-02 1995-06-07 Composition for sustained release of human growth hormone
US08/473,544 US5654010A (en) 1992-12-02 1995-06-07 Composition for sustained release of human growth hormone
PCT/US1996/008086 WO1996040072A2 (en) 1995-06-07 1996-06-03 Composition for sustained release of human growth hormone

Publications (2)

Publication Number Publication Date
IL122385A0 IL122385A0 (en) 1998-06-15
IL122385A true IL122385A (en) 2001-01-11

Family

ID=27044171

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12238596A IL122385A (en) 1995-06-07 1996-06-03 Composition for sustained release of human growth hormone

Country Status (22)

Country Link
EP (1) EP0831787B1 (xx)
JP (1) JPH11506740A (xx)
CN (1) CN1102854C (xx)
AT (1) ATE204468T1 (xx)
AU (1) AU708756B2 (xx)
BR (1) BR9608542A (xx)
CA (1) CA2223436A1 (xx)
CZ (1) CZ288147B6 (xx)
DE (1) DE69614685T2 (xx)
DK (1) DK0831787T3 (xx)
ES (1) ES2161366T3 (xx)
HK (1) HK1009089A1 (xx)
HU (1) HUP9900870A3 (xx)
IL (1) IL122385A (xx)
MX (1) MX9709698A (xx)
NO (1) NO316104B1 (xx)
NZ (1) NZ310644A (xx)
PL (1) PL184531B1 (xx)
PT (1) PT831787E (xx)
RU (1) RU2161502C2 (xx)
SK (1) SK281571B6 (xx)
WO (1) WO1996040072A2 (xx)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2224381A1 (en) * 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
ZA9711385B (en) 1996-12-20 1999-06-18 Takeda Chemical Industries Ltd Method of producing a sustained-release preparation
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
NZ508878A (en) 1998-05-15 2003-08-29 Genentech Inc IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
EP1953173B1 (en) 1999-06-15 2009-11-18 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
EP1686134A3 (en) 1999-12-01 2006-08-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1897945B1 (en) 1999-12-23 2012-01-18 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
ATE424457T1 (de) 2000-01-13 2009-03-15 Genentech Inc Menschliche stra6 polypeptide
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
WO2001072323A2 (en) 2000-03-24 2001-10-04 Genentech, Inc. Use of insulin for the treatment of cartilagenous disorders
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
ATE412009T1 (de) 2000-08-24 2008-11-15 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
WO2002053136A1 (fr) 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Preparations a liberation soutenue
WO2002092619A2 (en) 2001-05-14 2002-11-21 The Gouvernment Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
ES2554106T3 (es) 2001-06-21 2015-12-16 Genentech, Inc. Formulación de liberación sostenida
CA2477249A1 (en) 2002-02-25 2003-09-04 Genentech, Inc. Novel type-1 cytokine receptor glm-r
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
ATE425463T1 (de) 2003-06-06 2009-03-15 Genentech Inc Modulation der wechselwirkung zwischen hgf-beta- kette und c-met
KR100835786B1 (ko) 2003-07-08 2008-06-09 제넨테크, 인크. Ｉｌ-１７ａ／ｆ 이종 폴리펩티드 및 그의 치료 용도
KR101195291B1 (ko) 2003-12-11 2012-10-26 제넨테크, 인크. Ｃ－ｍｅｔ 이량체화 및 활성화를 억제하는 방법 및조성물
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
NZ550542A (en) 2004-03-30 2009-03-31 Nsgene As Therapeutic use of a growth factor, NsG33
JP2008518026A (ja) 2004-10-27 2008-05-29 ユニバーシティ・オブ・デンバー 副腎皮質刺激ホルモンアナログおよびこれに関連する方法
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
BRPI0518999A2 (pt) 2004-12-10 2008-12-23 Talima Therapeutics Inc composiÇÕes e mÉtodos para tratar condiÇÕes da unidade da unha
US7858843B2 (en) 2005-06-06 2010-12-28 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
WO2008018854A2 (en) 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
DE602006010072D1 (de) 2005-06-21 2009-12-10 Chen Gang Il-1 bindende antikörper und fragmente davon
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
US7931902B2 (en) 2005-08-15 2011-04-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
ATE491026T1 (de) 2005-08-24 2010-12-15 Univ Rockefeller Ply-gbs-lysinmutanten
CA2630432A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US20080032343A1 (en) 2005-12-22 2008-02-07 Genentech, Inc. Recombinant Production of Heparin Binding Proteins
EP2050335A1 (en) 2006-02-17 2009-04-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
CN101437536A (zh) 2006-03-23 2009-05-20 诺华有限公司 抗肿瘤细胞抗原抗体治疗
JP5290148B2 (ja) 2006-04-10 2013-09-18 ジェネンテック， インコーポレイテッド Ｄｉｓｈｅｖｅｌｅｄ（Ｄｖｌ）ＰＤＺ修飾因子
US20090288176A1 (en) 2006-04-19 2009-11-19 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
CN103356997A (zh) * 2006-08-31 2013-10-23 诺瓦提斯公司 用于口服递送的包含hgh 的药物组合物
EP2094306A2 (en) 2006-12-20 2009-09-02 XOMA Technology Ltd. Treatment of il-1-beta related diseases
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
AU2008287340A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
CN101945891A (zh) 2007-12-20 2011-01-12 爱克索马技术有限公司 治疗痛风的方法
GB0812742D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
MX2012004303A (es) 2009-10-15 2012-06-25 Genentech Inc Factores de crecimiento de fibroblasto quimericos con especificacion de receptor alterada.
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
JP5878477B2 (ja) 2010-01-15 2016-03-08 ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー 骨の治癒を加速するためのバナジウム化合物の使用
CN106983862A (zh) 2010-03-22 2017-07-28 弗·哈夫曼-拉罗切有限公司 对于稳定含有蛋白质的制剂有用的组合物和方法
MX2012012743A (es) 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
KR101924653B1 (ko) 2010-06-24 2018-12-03 제넨테크, 인크. 단백질-함유 제제를 안정화시키기 위한 알킬글리코시드 함유 조성물 및 방법
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
WO2012041328A1 (en) 2010-10-01 2012-04-05 Nsgene A/S Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
CA2814030C (en) 2010-10-08 2019-04-30 Shanghai Kexin Biotech Co., Ltd. Diagnostic and therapeutic uses of moesin fragments
KR101687060B1 (ko) 2010-10-08 2016-12-15 상하이 켁신 바이오테크 씨오., 엘티디. 모에신 조절제 및 그의 용도
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
WO2012149334A2 (en) 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
CN102875683B (zh) * 2011-07-11 2014-06-11 旭华（上海）生物研发中心有限公司 长效重组人生长激素的Fc融合蛋白
AU2012332767C1 (en) 2011-10-31 2017-02-02 Genentech, Inc. Antibody formulations
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
CN104520321A (zh) 2012-01-09 2015-04-15 斯克利普斯研究所 超长互补决定区及其用途
EP2802601B1 (en) 2012-01-09 2019-11-13 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
BR112015022025A8 (pt) 2013-03-14 2019-12-10 Hallux Inc composição e uso de um agente ativo
CN105283196B (zh) 2013-03-15 2018-10-12 贝丝以色列女执事医疗中心 用于产生和使用构象-特异性抗体的方法和组合物
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
AU2014290361B2 (en) 2013-07-18 2019-04-18 Taurus Biosciences, Llc Humanized antibodies with ultralong complementarity determining regions
ES2927607T3 (es) 2013-09-13 2022-11-08 Scripps Research Inst Agentes terapéuticos modificados y composiciones de los mismos
CA2926698C (en) 2013-10-15 2021-06-22 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
EP3057994B1 (en) 2013-10-15 2020-09-23 The Scripps Research Institute Peptidic chimeric antigen receptor t cell switches and uses thereof
CN104623639A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 白介素22二聚体在制备治疗胰腺炎药物中的应用
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
EP4212180A1 (en) 2013-12-18 2023-07-19 The Scripps Research Institute Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
NL2014230B1 (en) 2015-02-04 2016-10-12 Stichting Vu-Vumc Wound healing formulation.
MA41629A (fr) 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
CN107921098A (zh) 2015-06-17 2018-04-17 加州生物医学研究所 修饰的治疗剂及其组合物
EP3442562B1 (en) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd An il-22 dimer for use in treating necrotizing enterocolitis
CN110267982B (zh) 2016-10-19 2024-02-23 斯克利普斯研究所 具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
CN113660953A (zh) 2019-04-01 2021-11-16 豪夫迈·罗氏有限公司 用于稳定含蛋白质制剂的组合物和方法
TW202120551A (zh) 2019-08-12 2021-06-01 美商普瑞諾生物科技公司 藉由adcc靶向cd39表現細胞促進及增強t細胞介導免疫反應之方法及組合物
EP4048405A2 (en) 2019-10-24 2022-08-31 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
EP4329887A1 (en) 2021-04-28 2024-03-06 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
JP2024518433A (ja) 2021-05-06 2024-05-01 ホバ セラピューティクス エーピーエス 化学療法誘発性神経障害性疼痛の予防及び治療
AU2022405685A1 (en) 2021-12-10 2024-07-11 Hoba Therapeutics Aps Treatment of nociceptive pain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
DE69329295T2 (de) * 1992-12-02 2001-03-15 Alkermes Controlled Therapeutics, Inc. Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung
PT779806E (pt) * 1994-09-09 2001-02-28 Takeda Chemical Industries Ltd Preparacao de libertacao sustentada contendo um sal metalico de um peptido

Also Published As

Publication number Publication date
EP0831787B1 (en) 2001-08-22
NO975708D0 (no) 1997-12-05
CA2223436A1 (en) 1996-12-19
NO975708L (no) 1998-02-05
MX9709698A (es) 1998-07-31
NZ310644A (en) 1999-08-30
DK0831787T3 (da) 2001-12-17
PT831787E (pt) 2002-02-28
CZ288147B6 (en) 2001-05-16
CN1187120A (zh) 1998-07-08
PL323832A1 (en) 1998-04-27
HUP9900870A2 (hu) 1999-09-28
IL122385A0 (en) 1998-06-15
DE69614685T2 (de) 2002-06-27
ATE204468T1 (de) 2001-09-15
SK167197A3 (en) 1998-06-03
CZ390797A3 (cs) 1998-07-15
PL184531B1 (pl) 2002-11-29
AU6146996A (en) 1996-12-30
BR9608542A (pt) 1999-11-30
HUP9900870A3 (en) 2001-04-28
AU708756B2 (en) 1999-08-12
NO316104B1 (no) 2003-12-15
EP0831787A2 (en) 1998-04-01
DE69614685D1 (de) 2001-09-27
JPH11506740A (ja) 1999-06-15
RU2161502C2 (ru) 2001-01-10
CN1102854C (zh) 2003-03-12
WO1996040072A2 (en) 1996-12-19
ES2161366T3 (es) 2001-12-01
SK281571B6 (sk) 2001-05-10
HK1009089A1 (en) 1999-09-10
WO1996040072A3 (en) 1997-01-23

Similar Documents

Publication Publication Date Title
IL122385A (en) Composition for sustained release of human growth hormone
MX9709699A (es) Composicion para la liberacion sostenida de eritropoyetina no agregada.
DE3853853T2 (de) Verabreichungsformen für Pharmaka.
DE3685958T2 (de) Durch ultraschall gesteuerte polymere vorrichtungen zur wirkstoffabgabe.
WO2001043749A3 (en) Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
DE3689983T2 (de) Arzneimittel mit langsamer Wirkstofffreisetzung.
EP1570823A3 (en) Substained analgesia achieved with buprenorphine
ATE228832T1 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
CA2474698A1 (en) Polymer-based compositions for sustained release
EP1637164A3 (en) Improved formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5972384A (en) Use of biologically active glass as a drug delivery system
JPH07187994A (ja) 薬物放出制御製剤
EP1011637A4 (en) MODULATION OF DRUG LOAD IN MULTIFICULAR LIPOSOMES
UA29563C2 (uk) Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
AU7004194A (en) Drug system
US5342622A (en) Subdermal biocompatible implants
SK281461B6 (sk) Kolagénový prípravok na riadené uvoľňovanie účinných látok
AU5673399A (en) Compositions and methods for treating intracellular infections
WO2020166820A1 (ko) 피나스테라이드를 포함하는 마이크로 입자를 함유한 피하 주사용 조성물
EP0050650A1 (en) Prolonged action drug formulation
JPH06507634A (ja) 局所炎症反応の放出制御型薬物送達手段としての設計

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees